GRI Bio Featured in "Why Now" On-Demand Video Webcast
Video webcast now available here
GlobeNewsWire8/27/2026Neutral
GRI
GRI Bio Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.30M
P/E Ratio
—
EPS
$-2.83
Beta
-0.55
52W High
$80.36
52W Low
$1.36
50-Day MA
$1.73
200-Day MA
$7.12
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About GRI Bio Inc.
GRI Bio Inc. is an innovative biotechnology company focused on leveraging microbiome technology to develop cutting-edge therapeutics in immunology and oncology. By addressing the underlying causes of diseases rather than merely alleviating symptoms, GRI Bio aims to meet critical unmet medical needs with its transformative treatment options. The company has a strong pipeline of product candidates and actively engages in strategic collaborations to bolster its research initiatives. Positioned at the leading edge of the rapidly expanding microbiome therapeutics market, GRI Bio is dedicated to enhancing patient outcomes and has the potential to make significant contributions to the future of healthcare.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-9.68M |
| Operating Margin | 0.00% |
| Return on Equity | -142.00% |
| Return on Assets | -70.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.70 |
| Price-to-Book | 0.49 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.19M |
| Float | $2.19M |
| % Insiders | 0.38% |
| % Institutions | 4.28% |
Historical Volatility
HV 10-Day
139.67%
HV 20-Day
161.19%
HV 30-Day
139.38%
HV 60-Day
117.30%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($18.50 target)
2
BuyLatest News
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been selected for presentation at the 2026 European Respiratory Society (ERS) Congress, being held September 5-9, 2026 in Barcelona, Spain.
GlobeNewsWire8/24/2026Neutral
Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks
Bitcoin jumped 4.6% to $72,475.25 – a roughly 12% gain over the past two days after the digital asset was trading near $63,000 earlier this week.
New York Post8/20/2026Positive
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity
GlobeNewsWire6/18/2026Neutral
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20, 2026.
GlobeNewsWire5/18/2026Neutral
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities when used in combination
GlobeNewsWire5/14/2026Neutral
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market
GlobeNewsWire4/8/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GRI and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026